Core Viewpoint - The recent approval of the "Vitamin B6 Injection" by Jiangxi Gannan Haixin Pharmaceutical Co., Ltd. is expected to enhance market competitiveness, although it will not significantly impact the company's current operating performance [1][2]. Company Announcement Summary - Haixin Co., Ltd. reported a stock price of 7.01 yuan as of December 26, 2025, down 1.68% from the previous week [1]. - The stock reached a high of 7.24 yuan and a low of 7.00 yuan during the week [1]. - The company's current total market capitalization is 8.461 billion yuan, ranking 64th out of 151 in the chemical pharmaceutical sector and 2213th out of 5178 in the A-share market [1]. - The "Vitamin B6 Injection" has been approved by the National Medical Products Administration and is classified as a Class A drug under the national medical insurance and essential drug list, with an estimated sales volume of approximately 304 million yuan in public medical institutions for 2024 [1][2]. - The successful completion of the consistency evaluation for the generic drug is expected to improve product competitiveness [2].

Core Viewpoint - Shanghai Haixin Group's subsidiary, Jiangxi Gannan Haixin Pharmaceutical Co., Ltd., has received approval for its Vitamin B6 injection to pass the consistency evaluation of quality and efficacy for generic drugs, enhancing its market competitiveness and experience for future drug development [1][6]. Group 1: Drug Information - The drug is named Vitamin B6 Injection, in the form of an injection with a specification of 1ml:0.1g, classified as a chemical drug [1]. - The approval number for the drug is H20258295, and it has been granted a 12-month validity period [1]. - The drug is indicated for the prevention and treatment of Vitamin B6 deficiency, as well as for various conditions such as pregnancy-related issues and certain metabolic disorders [2][3][4]. Group 2: Market Situation - Vitamin B6 is a water-soluble vitamin that cannot be synthesized by the human body and must be obtained through diet or intravenous injection [7]. - The injection is classified as a Category A drug under national medical insurance and is included in the national essential drug list, indicating its widespread application in disease prevention and treatment [7]. - According to the Minet database, the sales revenue of Vitamin B6 injection in public medical institutions in China is projected to be approximately RMB 304 million in 2024 [7]. Group 3: Impact on the Company - The approval of Vitamin B6 injection enhances the market competitiveness of Jiangxi Gannan Haixin and contributes to the accumulation of experience for future drug development [6]. - The current operational performance of the company is not expected to be significantly impacted by this approval [6].

Group 1 - Zhuolang Intelligent's subsidiary plans to increase capital by 900 million yuan to its wholly-owned subsidiary in Xinjiang [1] - Zhenhua Heavy Industry signed a contract worth 1.149 billion yuan with Guangzhou Salvage Bureau for a deep-water crane ship construction project [2] - Ugreen Technology intends to issue H-shares and apply for listing on the Hong Kong Stock Exchange to enhance its global strategy [3] Group 2 - Guangsheng Nonferrous Metals will change its stock name to Zhongxi Rare Metals starting December 31, 2025 [4] - China Electric Research proposed a cash dividend of 2.5 yuan per 10 shares for the first three quarters of 2025 [5] - Chaoyan Co. is establishing a fund with professional investment institutions, aiming to raise 1 billion yuan [6] Group 3 - Silk Road Vision's subsidiary plans to sell 8.5% of Ruijun Technology for 52.7 million yuan [7] - Longgao Co.'s actual controller is transferring 4.37% of the investment development group's equity for 398 million yuan [8] - Weiteou signed a strategic cooperation agreement with Huaruixin Energy to develop new materials and applications [9][10] Group 4 - Annuoqi decided to terminate the investment in a 50,000-ton dye intermediate project due to market changes, with a total investment of 421 million yuan [12] - Akoli's subsidiary has entered trial production for a project with an annual capacity of 20,000 tons of polyether amine [13] - Ningbo Construction's subsidiary signed a construction contract worth 451 million yuan for a comprehensive utility tunnel project [14] Group 5 - Zhejiang Rongtai and Weichuang Electric plan to establish a joint venture in Thailand for R&D and production of mechatronic components [15] - Jiuzhoutong's subsidiary received a drug registration certificate for isopropazine injection [16] - Huaqin Technology's subsidiary signed a daily operation contract worth 392 million yuan [17] Group 6 - ST Meichen completed the sale of 100% equity in Hainan Meichen Ecological Development Co., Ltd. [18] - Pulite's LCP film products have begun mass production for a leading customer in the consumer electronics industry [19][20] - Nanjing Public Utility's major shareholder transferred 7.61% of the company's shares for 300 million yuan [21] Group 7 - Solar Energy terminated the investment in a 150 MW distributed photovoltaic project due to increased investment risks [22] - Yuntian Lifa won a 122 million yuan project for AI development in Longgang [23] - Changchun High-tech's subsidiary received acceptance for a clinical trial application for GenSci141 ointment [24] Group 8 - Changfei Optical Fiber's major shareholder completed a share reduction plan, selling 1.1 million shares for approximately 104.5 million yuan [25] - Sandam Membrane plans to apply for a comprehensive credit limit of up to 100 million yuan for 2026 [26] - Aisecurity received a government subsidy of 3.4611 million yuan [27] Group 9 - Stone Technology's H-share issuance has received approval from the China Securities Regulatory Commission [28] - Hongxing Development's subsidiary plans to suspend production to comply with national hazardous chemical relocation policies [29] - Guodian Nanzi's vice president and chief engineer resigned [30] Group 10 - Jianghe Group's subsidiary won a bid for a city renovation project in Haikou worth approximately 112 million yuan [31] - Gaotie Electric's subsidiary won a bid for a railway project worth 59.0317 million yuan [32] - Huicheng Co. plans to introduce a new partner to its major shareholder [33] Group 11 - Pumen Technology's folic acid testing kit received a medical device registration certificate [34] - Hai Xin Co.'s vitamin B6 injection passed the consistency evaluation for generic drugs [35] - Taiji Group's shareholder plans to merge with its subsidiary [36] Group 12 - Shengyi Electronics adjusted the maximum repurchase price to no more than 144.36 yuan per share [37]

Core Viewpoint - The company, Haixin Co., Ltd. (600851.SH), announced that its subsidiary, Jiangxi Gannan Haixin Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the supplement application of the chemical drug "Vitamin B6 Injection," which has passed the consistency evaluation of generic drug quality and efficacy [1] Group 1 - The approved drug, Vitamin B6 Injection, is primarily indicated for the prevention and treatment of Vitamin B6 deficiency and for treating isoniazid poisoning [1] - Additional indications include use during pregnancy, radiation sickness, and vomiting caused by anticancer drugs, as well as seborrheic dermatitis [1] - The drug is also indicated for total parenteral nutrition and for nutritional deficiencies due to inadequate intake, as well as for progressive weight loss [1] Group 2 - Increased demand for Vitamin B6 may arise in conditions such as pregnancy and lactation, hyperthyroidism, burns, chronic infections, fever, congenital metabolic disorders, congestive heart failure, long-term dialysis, and malabsorption syndromes associated with liver and biliary diseases [1] - The drug is also indicated for gastrointestinal diseases, including celiac disease, tropical enteritis, localized enteritis, and persistent diarrhea, as well as post-gastrectomy [1] - It is specifically indicated for newborns with hereditary Vitamin B6 dependency syndrome [1]

Core Viewpoint - The company HaiXin Co., Ltd. has received approval from the National Medical Products Administration for its generic drug "Vitamin B6 Injection," which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Company Summary - HaiXin Co., Ltd. announced on December 26 that its subsidiary Jiangxi Gannan HaiXin Pharmaceutical Co., Ltd. has obtained the approval notice for the supplemental application of the chemical drug "Vitamin B6 Injection" [1] - The approval indicates that the drug meets the required standards for quality and efficacy, which is crucial for its market entry and competitiveness [1]

南财智讯12月26日电，海欣股份公告，控股子公司江西赣南海欣药业股份有限公司收到国家药监局核准 签发的化学药品"维生素B6注射液"的《药品补充申请批准通知书》，维生素B6注射液通过仿制药质量 和疗效一致性评价。维生素B6注射液为维生素类药，主要用于维生素B6缺乏的预防和治疗，防治异烟 肼中毒，也可用于妊娠、放射病及抗癌药所致的呕吐、脂溢性皮炎等。该药品为国家医保甲类品种和国 家基药目录品种，米内网数据库显示，2024年全国公立医疗机构销售额约为人民币3.04亿元。此次通过 一致性评价有助于提升产品的市场竞争力，为后续新药研发积累经验，但对公司目前经营业绩不会产生 重大影响。公司提示，药品销售受国家政策、招标采购、市场环境等因素影响，存在不确定性，敬请投 资者注意防范投资风险。 ...

Core Viewpoint - Ganhai Xin's vitamin B6 injection has passed the consistency evaluation of quality and efficacy for generic drugs, enhancing its market competitiveness, although it will not significantly impact the company's current operating performance [1] Company Summary - Ganhai Xin, a subsidiary of Haixin Co., has developed a vitamin B6 injection primarily used for preventing and treating vitamin B6 deficiency and as a nutritional supplement for specific populations [1] - The product adheres to the drug registration standards set by the National Medical Products Administration [1] Industry Summary - The estimated sales revenue for public medical institutions in China for vitamin B6 injections is approximately 304 million yuan in 2024 [1]

Core Viewpoint - The company announced that its subsidiary, Jiangxi Gannan Haixin Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the supplement application of the chemical drug "Vitamin B6 Injection," which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The approval signifies a regulatory milestone for the company, enhancing its product portfolio in the pharmaceutical sector [1] - The "Vitamin B6 Injection" is now positioned to enter the market, potentially increasing the company's revenue streams [1] - The successful completion of the consistency evaluation indicates the company's commitment to maintaining high-quality standards in its pharmaceutical offerings [1]

Market Overview - The market showed mixed performance with the Shanghai Composite Index slightly up by 0.05% while the Shenzhen Component and ChiNext Index both fell over 1% [2] - The number of rising stocks exceeded 2600, indicating a generally positive sentiment despite some declines in specific sectors [2] Key Sectors - **Hainan Free Trade Zone**: Stocks such as Intercontinental Oil and Gas and Haima Automobile reached their daily limit up, driven by positive sentiment regarding the alignment of the China-ASEAN Free Trade Area 3.0 with Hainan's development [4] - **Coal Sector**: Antai Group hit the daily limit up, with other coal stocks also performing well. The price of coking coal increased by 10.29% over the last 60 days, reaching 1581.25 RMB per ton [5] Policy and Corporate Developments - **AI and Manufacturing**: The Ministry of Industry and Information Technology emphasized the importance of integrating AI into manufacturing, aiming to enhance productivity and innovation across key industries [7] - **Leadership Change at Kweichow Moutai**: A change in leadership occurred with Chen Hua taking over as the new chairman, which may influence the company's strategic direction [8] Financial Insights - **OpenAI's Revenue**: OpenAI's CEO expressed optimism about the company's revenue, claiming it exceeds the previously reported $13 billion, despite ongoing losses [9] - **Shishi Pharmaceutical's Approval**: Shishi Pharmaceutical's Vitamin B6 injection received approval for consistency evaluation, which could enhance its market position [10] Investment Outlook - **Solid-State Battery Technology**: The solid-state battery sector is expected to see accelerated capital expenditure and a potential reversal in supply-demand dynamics, with significant growth anticipated from 2025 onwards [11] - **Energy Storage Market**: The energy storage market is poised for growth driven by economic factors and increasing demand from data centers, with lithium battery demand expected to grow over 30% by 2026 [11]

Core Viewpoint - China Medical (600056.SH) announced that its wholly-owned subsidiary Tianfang Pharmaceutical received approval from the National Medical Products Administration for the Vitamin B6 injection, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1: Product Approval and Market Impact - The Vitamin B6 injection is primarily used for the prevention and treatment of Vitamin B6 deficiency, as well as for conditions such as isoniazid poisoning, pregnancy-related issues, radiation sickness, and vomiting caused by anticancer drugs [1] - The original product was developed by Fujisawa Pharmaceutical Co., Ltd. in June 1957 and received FDA approval for the U.S. market in August 1972, with a specification of 1ml:0.1g [1] - Currently, the original product is not imported or available in the domestic market [1] Group 2: Policy and Competitive Advantage - According to national policies, drugs that pass the consistency evaluation will receive greater support in areas such as medical insurance payments and procurement by medical institutions [1] - The approval of Tianfang Pharmaceutical's Vitamin B6 injection enhances the product's market competitiveness and is expected to further expand its market share [1]